Selecting a Pharmaceutical Company from Northeast Asia for Investment Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

Home >> Ivey Case Solutions >> Selecting a Pharmaceutical Company from Northeast Asia for Investment

Joe Clift, co-founder and managing partner of the private investment firm Smith Partners LLC in New York, a fund manager of the company developing the market for several industries. He planned to add one company from Northeast Asia to drive growth in its portfolio the pharmaceutical industry, and focused on three prominent pharmaceutical companies: Takeda Pharmaceutical Company Ltd. of Japan, Dong-pharmaceutical company in Korea, and Sinovac Biotech Company Ltd. from China. All three companies have shown strong growth in their respective markets for many years. Japan, the number one pharmaceutical drug users in Asia, is also the second largest single market in the world after the United States. Japan sales of $ 60 billion, or about 11 percent of the world market in 2006. Korea has maintained a competitive domestic market supported by excellent national health insurance system and a high power of the study. Korea was the fourteenth largest consumer of drugs in the global market since 2008. China, which is one of the fastest growing pharmaceutical markets, was the second largest consumer of pharmaceutical drugs in Asia. With the ever growing population of senior citizens in the North-East Asia, managing partner predicted strong growth potential in preparations for the treatment of chronic diseases in these emerging markets. What companies should Clift choose between the three companies, and why? "Hide
by Ho-Young Lee, James Russell Shaw Jr., Kyung Cho Moon Source: Richard Ivey School of Business Foundation 8 pages. Publication Date: September 17, 2012. Prod. #: W12196-PDF-ENG